Non-primate lentiviral vector administration in the TMJ

Area of Science:

• Biomedical Engineering
• Gene Therapy
• Otolaryngology

Background:

• Temporomandibular joint (TMJ) disorders represent a significant clinical challenge.
• Gene therapy offers a novel therapeutic avenue for managing TMJ disorders.
• Understanding the efficacy of gene delivery vectors within the TMJ is crucial.

Purpose of the Study:

• To evaluate the effects and efficacy of lentiviral vectors in the temporomandibular joint.
• To determine the biodistribution and transduction capabilities of lentiviral vectors within TMJ tissues.
• To explore the potential of lentiviral vectors for targeted gene delivery in the TMJ.

Main Methods:

• Injection of a defective feline immunodeficiency virus (FIV) vector carrying the lacZ reporter gene into the articular joint space.
• Analysis of lacZ expression using Polymerase Chain Reaction (PCR), X-gal histochemistry, and beta-galactosidase immunocytochemistry.
• Assessment of vector transduction in hard and soft tissues of the TMJ and associated neural pathways.

Main Results:

• Successful transduction of both hard and soft tissues within the temporomandibular joint.
• Detection of reporter gene expression in a subset of primary sensory neurons of the ipsilateral trigeminal ganglion.
• Evidence of retrograde transport of the lentiviral vector from peripheral nerve fibers to the neuronal nucleus.

Conclusions:

• Lentiviral vectors demonstrate efficient gene transfer capabilities within the temporomandibular joint.
• The observed transduction of trigeminal ganglion neurons suggests potential for targeting pain pathways.
• Lentiviral vectors represent a promising platform for gene therapy applications in managing TMJ pain.